Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved a 200 mg/mL autoinjector of Benlysta, a B-lymphocyte ...

There are multiple chapters near you. Select your preferred chapter.